Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse
Autor: | R. Nagarajah, Kenneth W. Gross, Richard K. Albert, A.K. Ratty, Gavin S. Dawe, D.E. Casey |
---|---|
Rok vydání: | 2010 |
Předmět: |
Olanzapine
Mice Transgenic Pharmacology Hyperkinesis Motor Activity Mice Mice Neurologic Mutants Pimozide Dopamine Dopamine receptor D2 medicine Haloperidol Animals Ziprasidone Clozapine Analysis of Variance Chakragati mouse Dose-Response Relationship Drug business.industry Receptors Dopamine D2 General Neuroscience Mice Inbred C57BL Disease Models Animal Inhibition Psychological Receptors Serotonin Schizophrenia business medicine.drug Antipsychotic Agents Protein Binding |
Zdroj: | Neuroscience. 171(1) |
ISSN: | 1873-7544 |
Popis: | The chakragati (ckr) mouse has been proposed as a model of aspects of schizophrenia. The mice, created serendipitously as a result of a transgenic insertional mutation, exhibit spontaneous circling, hyperactivity, hypertone of the dopamine system, reduced social interactions, enlarged lateral ventricles, deficits in pre-pulse inhibition of acoustic startle and deficits in latent inhibition of conditioned learning. In this study, the dose-dependent effects of antipsychotic drugs (haloperidol, pimozide, risperidone, clozapine, olanzapine, ziprasidone, quetiapine and aripiprazole) on the spontaneous hyperactivity of the mice were investigated. All the antipsychotic drugs tested dose-dependently suppressed spontaneous hyperactivity. Aripriprazole, which is known to be a dopamine D2 receptor partial agonist, exhibited a tri-phasic dose-response, initially suppressing hyperactivity at low doses, having little effect on hyperactivity at intermediate doses, and suppressing activity again at high doses. These data suggest that the spontaneous circling and hyperactivity of the ckr mouse may allow screening of candidate antipsychotic compounds, distinguishing compounds with aripriprazole-like profiles. |
Databáze: | OpenAIRE |
Externí odkaz: |